APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
High-grade Serous Ovarian Cancer
Conditions
High-grade Serous Ovarian Cancer
Trial Timeline
Jul 31, 2017 → Jul 10, 2019
NCT ID
NCT03268382About APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
APR-246 + Pegylated Liposomal Doxorubicin Hydrochloride (PLD) is a phase 2 stage product being developed by Aprea Therapeutics for High-grade Serous Ovarian Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03268382. Target conditions include High-grade Serous Ovarian Cancer.
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03268382 | Phase 2 | Completed |
Competing Products
8 competing products in High-grade Serous Ovarian Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| azenosertib | Zentalis Pharmaceuticals | Phase 2 | 32 |
| Sepantronium Bromide | Cothera Bioscience | Phase 2 | 29 |
| Mirvetuximab Soravtansine | AbbVie | Phase 2 | 42 |
| Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + Docetaxel | Merck | Phase 2 | 35 |
| BMS-986463 | Bristol Myers Squibb | Phase 1 | 36 |
| Mebendazole | Brain Biotech | Phase 1 | 19 |
| Ex-Vivo expanded autologous IL-8 receptor (CXCR2) modified CD70 CAR (8R-70CAR) T cells | Brain Biotech | Phase 1 | 23 |
| APR-246 + Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD) | Aprea Therapeutics | Phase 1/2 | 22 |